Comirnaty market forecast to double by 2030 as booster demand stays strong

The Business Research Company says the global Comirnaty (tozinameran) market will grow from $8.26 million in 2025 to $21.81 million by 2030, fueled by booster demand, mRNA adoption and pandemic preparedness spending. North America held the largest regional share in 2025, while the report highlights rising infectious disease pressure and personalized medicine as key demand drivers.

Why it matters: - Comirnaty remains a benchmark mRNA vaccine market tied to COVID-19 prevention, booster programs and broader vaccine platform adoption. - The report points to continued demand from governments, health systems and vaccine makers as infectious disease threats persist. - Market growth also signals wider commercial momentum for mRNA technology beyond the original COVID-19 rollout.

What happened: - The Business Research Company released its Comirnaty (Tozinameran) Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035. - The report sizes the market at $8.26 million in 2025 and projects $10.05 million in 2026. - The report forecasts the market will reach $21.81 million by 2030. - The report says North America held the largest share of the global market in 2025. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report is available with a free sample and a full market report.

The details: - The report says the market grew on the back of the global COVID-19 outbreak, emergency regulatory approvals, government vaccination initiatives, rapid manufacturing scale-up and clinical efficacy data. - The forecast period is driven by booster vaccine demand, broader uses for mRNA technology, government stockpiling, better cold-chain storage and rising global immunization coverage. - The report highlights widespread mRNA vaccine adoption, expanded booster programs, pandemic preparedness, lipid nanoparticle delivery improvements and large-scale vaccination campaigns as major trends. - Comirnaty is an mRNA-based vaccine designed to prevent COVID-19. - The vaccine uses lipid nanoparticles to deliver genetic instructions to cells. - The cells produce a protein similar to the SARS-CoV-2 spike protein, which triggers an immune response. - The immune response helps protect against infection and reduces the severity of COVID-19, including hospitalization and death. - The report identifies rising infectious disease prevalence as a major growth driver. - Infectious disease spread is linked in the report to international travel, urbanization, deforestation, population growth, climate change, antimicrobial resistance, limited healthcare access, poor sanitation and zoonotic transmission. - The report says Comirnaty supports vaccination efforts by helping reduce transmission and prevent severe illness. - In August 2024, the UK Health Security Agency reported 368 measles cases in England in 2023, nearly seven times the 53 cases reported in 2022. - The UKHSA data showed the West Midlands and London accounted for 44% and 33% of those cases. - The report also names personalized medicine as a growing driver. - Personalized medicine tailors treatment to a person’s genetic profile, environment and lifestyle. - The report says advances in genomic technologies, molecular biology and precision diagnostics are increasing demand for targeted therapies. - Comirnaty’s mRNA platform allows rapid tailoring of vaccines to specific genetic characteristics, according to the report. - In February 2024, the Personalized Medicine Coalition said the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six approvals in 2022.

Between the lines: - The market numbers are small in absolute dollar terms, but the growth rate is steep, which suggests the report is tracking a specialized vaccine segment rather than a broad consumer market. - The report frames Comirnaty as part of a larger shift toward flexible, quickly adaptable biologic platforms. - Regional coverage and the added analytics tools in the 2026 report suggest the publisher is targeting investors, strategists and commercial teams looking for planning data rather than a simple product overview.

What's next: - The report expects the market to keep expanding through 2030 as booster programs and mRNA use cases widen. - Governments and health systems are likely to remain important buyers if stockpiling and preparedness budgets hold. - Improvements in delivery systems and cold-chain logistics could support broader deployment. - The publisher says the 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspot infographics, and future trend analysis.

The bottom line: - Comirnaty’s market outlook is being driven less by one-time pandemic demand and more by sustained booster use, infectious disease pressure and the broader commercialization of mRNA technology.